Please login to the form below

Not currently logged in
Email:
Password:

Ganymed Pharmaceuticals

This page shows the latest Ganymed Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Astellas agrees €800m deal to buy Belgian biotech Ogeda

Astellas agrees €800m deal to buy Belgian biotech Ogeda

This is the second major deal for Astellas in a few months, following a $1.4bn acquisition of Germany's Ganymed Pharmaceuticals that gave it a gastric cancer antibody (IMAB362) in

Latest news

  • Astellas buys Ganymed to boost immuno-oncology pipeline Astellas buys Ganymed to boost immuno-oncology pipeline

    Astellas has agreed to pay 422m upfront to buy Ganymed Pharmaceuticals, a German biopharma company specialising in antibody-based cancer drugs. ... If all goes according to plan, Ganymed's shareholders could pick up an additional 860m in milestones,

  • Hexal co-founders continue biotech buy up

    The Struengmanns already hold stakes in German biotechnology companies including 4SC and Ganymed Pharmaceuticals, which is developing monoclonal antibody therapeutics to fight solid cancer tumours.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics